1313409-07-2

Basic information

• Product Name: 1-benzyl-3-bromo-4-nitro-1H-indazole
• Synonyms: 1-benzyl-3-bromo-4-nitro-1H-indazole
• CAS NO: 1313409-07-2
• Molecular Weight: 332.156
• Mol File: 1313409-07-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-benzyl-3-bromo-4-nitro-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-3-bromo-4-nitro-1H-indazole(1313409-07-2)
• EPA Substance Registry System: 1-benzyl-3-bromo-4-nitro-1H-indazole(1313409-07-2)

Safety Data

• Hazardous Substances Data: 1313409-07-2(Hazardous Substances Data)

Upstream product

• 74209-17-9 3-bromo-4-nitro-1H-indazole 
• 100-44-7 benzyl chloride 
• 70261-58-4 1-benzyl-4-nitro-1H-indazole 
• 2942-40-7 nitro-4 indazole 
• 100-39-0 benzyl bromide 

Downstream Products

• 1313409-08-3 1-benzyl-3-cyclopropyl-4-nitro-1H-indazole 
• 1313409-10-7 1-benzyl-3-cyclopropyl-1H-indazol-4-amine 
• 1313407-31-6 N-(1-benzyl-3-cyclopropyl-1H-indazol-4-yl)-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors

Colony stimulating factor-1 receptor (CSF-1R or FMS) and it ligand, CSF-1, signaling regulates the differentiation and function of tumor-associated macrophages (TAMs) that play an important role in tumor progression. Derivatives of thieno[3,2-d]pyrimidine were synthesized and evaluated as kinase inhibitors of FMS. The most representative compound 21 showed strong activity (IC50 = 2 nM) against FMS kinase and served as candidate for proof of concept. Anti-tumor activity alone and/or in combination with paclitaxel was examined via a tumor cell growth inhibition assay and via an in vitro tumor invasion assay using human breast adenocarcinoma cells.